CD109 is identified as a potential nasopharyngeal carcinoma biomarker using aptamer selected by cell-SELEX
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 2403 views | HTML 2856 views | ?
Wenting Jia1, Caiping Ren1, Lei Wang1, Bin Zhu1, Wei Jia1, Menghui Gao1, Fei Zeng2, Liang Zeng3, Xiaomeng Xia4, Xiaobing Zhang5, Ting Fu5, Shasha Li1, Can Du6, Xingjun Jiang6, Yuxiang Chen7, Weihong Tan5, Zilong Zhao5, Weidong Liu1
1Cancer Research Institute, Collaborative Innovation Center for Cancer Medicine, Key Laboratory for Carcinogenesis of Chinese Ministry of Health, School of Basic Medical Science, Central South University, Changsha, Hunan, P. R. China
2Department of Gynecology and Obstetrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China
3Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China
4Department of Gynaecology and Obstetrics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China
5Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Bio Sensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, and Collaborative Research Center of Molecular Engineering for Theranostics, Hunan University, Changsha, Hunan, P. R. China
6Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China
7Hepatobiliary & Enteric Surgery Research Center, Central South University, Changsha, Hunan, P. R. China
Caiping Ren, email: [email protected]
Zilong Zhao, email: [email protected]
Weidong Liu, email: [email protected]
Keywords: aptamer, cell-SELEX, nasopharyngeal carcinoma, biomarker discovery, CD109
Received: November 06, 2015 Accepted: May 17, 2016 Published: July 11, 2016
Nasopharyngeal carcinoma (NPC) is one of the most prevailing cancers in southern China and southern Asia. Because of the nonspecific symptoms and lack of effective biomarker, most patients are diagnosed at advanced stages, resulting in poor 5-year survival rate. To identify a novel NPC biomarker facilitating early detection and effective therapy of NPC, a two-step strategy consisting of cancer cell-Systematic Evolution of Ligands by EXponential enrichment (cell-SELEX) procedure and aptamer-based purification approach was developed. Using cell-SELEX procedure, four aptamers (S3, S5, S12 and S27) differentiating the molecular differences between NPC cells and NP cells were successfully screened. Then, using aptamer-based protein purification, membrane protein CD109 was identified as the target of aptamer S3. CD109 protein was further identified to be over-expressed in NPC cell lines and clinic tissues, but not or low in NP cell line and clinic NP tissues, detected by western blot and immunohistochemistry experiments. Our study demonstrated that CD109 identified by cell-SELEX and aptamer-based purification strategy might be used as a potential NPC biomarker for early diagnosis and targeted therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.